Therapeutic area: Cardiology/Vascular Disease

What are the considerations of treating CAD beyond ASA? Is it time for a new gold standard?

Is there a new gold standard to prevent strokes in the CAD Patient and the AF Patient?

Managing Both the High-Risk CAD Patient and the Frail, Renally-Impaired AF Patient: What you need to know

Hot Topics in Vascular Protection for the CAD Patient and AF Patient

Dispelling myths in AF: Managing the challenges of elderly, frail and/or renally impaired patients

How to Manage the Risks of CV Events and Limb Events of the CAD+PAD Patient

Les NACO chez les patients âgés et vulnérables : Que devrions-nous savoir?

Quelles sont les considerations de traiter la coronopathie au-delà de l'AAS? Est-ce le temps d'établir un nouveau standard?

How to Manage the Risks of CV Events and Limb Events of the CAD+PAD Patient

How to Manage the Risks of CV Events and Limb Events of the CAD+PAD Patient

Les NACO chez les patients âgés et vulnérables : Que devrions-nous savoir?

February 13, 2020

Optimizing Heart Failure Therapy - The Time is Now: Putting Evidence into Practice

December 5, 2019

15 min. Highlights from The Great Debate: Aspirin, DAPT or dual pathway inhibition for secondary prevention in stable ASCVD patients?

October 26, 2019

Women and CV Disease: Closing Care Gaps & Assessing Risk

Highlights from the Latest ODYSSEY OUTCOMES Data: The Role of PCSK9 Inhibition Post-ACS

February 21, 2019

Faits saillants des toutes dernières données de l’étude ODYSSEY OUTCOMES : Rôle de l’inhibition de la PCSK9 après un SCA

February 13, 2019

Highlights from the Latest ODYSSEY OUTCOMES Data: The Role of PCSK9 Inhibition Post-ACS

February 13, 2019

Traitement anticoagulant chez les patients atteints d’insuffisance rénale

November 14, 2018

Anticoagulation in Patients with Renal Impairment

October 10, 2018

Prise en charge de l’anticoagulothérapie prolongée dans les cas de TEV

Managing Extended Anticoagulant Therapy in VTE

Ask the Experts: Hot Topics in Heart Failure Management